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We read with interest the letter by Ponzetto and co-workers [1] commenting on 
our recently published Point of View paper [2]. They propose the hypothesis that 
testing for Helicobacter pylori (HP) and, when positive, managing that underling 
infection might improve the current management of some patients with 
antiphospholipid syndrome (APS). Of note, they highlighted that HP’s eradication 
might result in loss of antiphospholipid antibodies (aPL)[3]. There are several 
mechanisms through which pathogens can initiate or perpetuate autoimmunity 
and, while the factors causing production of aPL remain undefined, there is 
evidence that molecular mimicry is one of the mechanisms by which 
experimental APS can occur in association with certain pathogens [4]. However, 
when reviewing the available data on the topic, Abdel-Wahab at al. showed that, 
although the development of aPL with all traditional manifestations of APS were 
observed after variety of infections (mainly chronic viral infections including HIV 
and HCV), the causal relationship between infections and APS is still on debate 
[5].  Clinical evidences support that infections can trigger the development of 
catastrophic APS [6]; nevertheless, the possible contribution of various 
infections in the pathogenesis of APS need further longitudinal and controlled 
studies to establish the incidence, and to better quantify the risk and the 
outcomes of aPL-related events after infection.  
Finally, an important question still remains: is the aPL negativizationenough to 
change the therapeutic approach in a patient with APS? Recent data suggest that 
persistent negative aPL profile is not an indication to interrupt oral 
anticoagulant therapy as patients are still at high risk of recurrences [7]. 
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